Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06723756 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT06723756 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 105 participants.
The verdict
NCT06723756, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
This study aims to assess the bioequivalence of the total systemic exposure and safety of budesonide, glycopyrronium, and formoterol (160/14.4/4.8 µg/actuation) when administered as BGF MDI HFO compared with BGF MDI HFA in healthy participants.
Interventions
- DRUG Treatment A: BGF MDI HFO
- DRUG Treatment B: BGF MDI HFA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2025-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06723756
The ClinicalTrials.gov registry entry for NCT06723756 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Treatment A: BGF MDI HFO is the first listed.
NCT06723756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06723756 about?
NCT06723756 is a clinical study titled "A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults". This study aims to assess the bioequivalence of the total systemic exposure and safety of budesonide, glycopyrronium, and formoterol (160/14.4/4.8 µg/actuation) when administered as BGF MDI HFO compared with BGF MDI HFA in healthy participants.
What is the current status of trial NCT06723756?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2025-01-23. Estimated completion is 2025-06-01.
What interventions are being tested in trial NCT06723756?
The interventions under investigation include: Treatment A: BGF MDI HFO (DRUG), Treatment B: BGF MDI HFA (DRUG).
Who is sponsoring clinical trial NCT06723756?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.